"10.1371_journal.pone.0017491","plos one","2011-03-02T00:00:00Z","Sharad P Adekar; Andrew T Segan; Cindy Chen; Rodney Bermudez; M D Elias; Bernard H Selling; B P Kapadnis; Lance L Simpson; Paul M Simon; Scott K Dessain","Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America; Immunome, Inc., Wynnewood, Pennsylvania, United States of America; Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America; Impact Biologicals, Inc. Wallingford, Pennsylvania, United States of America; Department of Microbiology, University of Pune, Pune, India; Augmenta Biologicals, LLC, Wynnewood, Pennsylvania, United States of America","Conceived and designed the experiments: SPA ATS MDE BHS LLS PMS SKD. Performed the experiments: SPA ATS CC RB MDE BHS PMS. Analyzed the data: SPA ATS MDE BPK LLS PMS SKD. Contributed reagents/materials/analysis tools: SPA MDE BHS LLS PMS. Wrote the paper: SPA ATS MDE PMS SKD. Edited the manuscript: BHS BPK LLS.","The authors have read the journals policy and have the following conflicts: SPA and RB are part-time employees of Immunome, Inc., a company that has optioned rights to the antibodies described in this report. BHS is the president of Impact Biologicals, Inc. PMS is the inventor of the FP and the President of Augmenta, LLC. SKD is a founder and Chief Scientific Officer of Immunome, Inc. and has an equity interest in the company. SKD does not receive research support or consulting fees from Immunome, Inc., Augmenta Biologicals, LLC, or Impact Biologicals, Inc. A provisional US Patent application has been filed on the experiments described, Toxin Clearance, Inventors SPA, SKD, PMS, and has been assigned to LIMR and Augmenta, LLC. These relationships do not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","03","Sharad P Adekar","SPA",10,TRUE,7,7,7,5,TRUE,TRUE,FALSE,0,NA,FALSE
